Modalis Therapeutics (TSE:4883) Notes Receivable: 円0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4883 Modalis Therapeutics Corp TSE:4883
20 GF Score
Price 円34.00
! 2 Warning Signs
View Full Analysis

What is Modalis Therapeutics Notes Receivable?

Modalis Therapeutics TSE:4883 +3.03% 20 Notes Receivable is 円0.00 Mil as of Dec. 2025. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Modalis Therapeutics's Notes Receivable for the quarter that ended in Dec. 2025 was 円0.00 Mil.

Modalis Therapeutics Notes Receivable Related Terms

Modalis Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Modalis Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics Notes Receivable Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Modalis Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4883
20GF Score
Modalis Therapeutics Corp TSE:4883
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modalis Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of 円0.00 Mil mean?
Modalis Therapeutics (TSE:4883) has a Notes Receivable of 円0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Modalis Therapeutics and its competitors.
Is Modalis Therapeutics' Notes Receivable too high?
Modalis Therapeutics' current Notes Receivable is 円0.00 Mil. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Notes Receivable compare to ZTS and UTHR?
Modalis Therapeutics' Notes Receivable of 円0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Modalis Therapeutics and its competitors. Modalis Therapeutics's current Notes Receivable is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Notes Receivable of 円0.00 Mil. The current Notes Receivable is 円0.00 Mil. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Notes Receivable is 円0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modalis Therapeutics Business Description

Address 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score

Get the complete analysis for TSE:4883

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円34.00
Price